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Abstract
Background: Primary treatment of carcinoma of the oro-/hypopharynx or larynx may consist of combined
platinum-containing chemoradiotherapy. In order to improve clinical outcome (i.e. local control/overall survival),
combined therapy is intensified by the addition of the EGFR inhibitor cetuximab (Erbitux®). Radiation therapy (RT) is
carried out as intensity-modulated RT (IMRT) to avoid higher grade acute and late toxicity by sparing of
surrounding normal tissues.
Methods/Design: The REACH study is a prospective phase II study combining chemoradiotherapy with
carboplatin/5-Fluorouracil (5-FU) and the monoclonal epidermal growth factor-receptor (EGFR) antibody cetuximab
(Erbitux®) as intensity-modulated radiation therapy in patients with locally advanced squamous-cell carcinomas of
oropharynx, hypopharynx or larynx.
Patients receive weekly chemotherapy infusions in the 1
st and 5
th week of RT. Additionally, cetuximab is adminis-
tered weekly throughout the treatment course. IMRT is delivered as in a classical concomitant boost concept (bid
from fraction 16) to a total dose of 69,9 Gy.
Discussion: Primary endpoint of the trial is local-regional control (LRC). Disease-free survival, progression-free
survival, overall survival, toxicity, proteomic and genomic analyses are secondary endpoints. The aim is to explore
the efficacy as well as the safety and feasibility of this combined radioimmunchemotherapy in order to improve
the outcome of patients with advanced head and neck cancer.
Trial registration: ISRCTN87356938.
Background
Long-term outcome for patients with advanced squa-
mous cell carcinoma of the head and neck (SCCHN) is
still disappointing. For locally advanced or unresectable
SCCHN without evidence of distant metastases, com-
bined chemoradiotherapy is a proven curative treatment
option. Due to the sometimes marked side effects in
standard chemoradiation regimens using altered-fractio-
nation 3 D conformal radiation techniques, intensifica-
tion is rarely clinically possible. In view of further
improvement of clinical outcome by intensification of
the combined treatment approach, toxicity of the estab-
lished treatment regimen needs to be reduced by
employing modern radiotherapy techniques such as
IMRT.
A meta-analysis from the MARCH Collaborative
Group has shown an absolute survival benefit of 6.5% at
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yet still significant survival benefit was found for all che-
moradiotherapy algorithms, whether it was neoadjuvant,
adjuvant or concomitant with 4.5% at 5 years [1]. This
effect was mainly caused by an increased local control
and only to a lesser extent by reduction of distant
metastases. The MARCH data showed no difference in
response to chemoradiotherapy with respect to tumor
site (oral cavity, oro-, hypopharynx, larynx). A published
meta-analysis even found an overall survival benefit of
12 months when adding chemotherapy to normally frac-
tionated radiotherapy or altered fractionated schedules
[2]. However, no increased benefit was found when
using hyperfractionated or accelerated fractionation
[conventional fraction of 1.8 or 2.0 Gy per day] in this
meta-analysis.
Altered fractionation schedules, especially hyperfrac-
tionation, lead to a significant improvement in overall
survival if radiation therapy is performed as a single
therapy modality. Accelerated radiation therapy alone,
however, does not increase overall survival when given
as split course or extremely accelerated treatments with
decreased total dose. Bourhis et al. came to the same
conclusion in their recent meta-analysis: the authors
found that altered fractionation schedules showed only a
small but again significant, absolute survival benefit
when compared to conventional radiotherapy [3]. Also,
survival benefit was significantly higher with hyperfrac-
tionated radiotherapy than with accelerated radiother-
apy. In addition, altered fractionation regimen resulted
in increased locoregional control in all patients though
younger patients seemed to benefit most.
In view of the MARCH data regarding the type of
chemotherapy, most positive trials combined radiother-
apy with three cycles of concurrent cisplatin 100 mg/m
2
[1] which can be considered the standard regimen.
Budach et al. revealed the highest prolongation of survi-
val of 24 months in combining 5-FU and radiotherapy
[2]. Cisplatin- and carboplatin-based chemotherapy and
radiotherapy prolonged the survival to 16.8 and
6.7 months, respectively.
However, it is a clinical fact that a significant percen-
tage of patients do not receive their full planned course
of combination treatment due to excessive toxicity,
hence the need arises to optimize these regimen. Var-
ious options exist: first of all, the use of more tolerable
chemotherapy combinations, second the integration of
molecular targeted drugs and third the use of modern
concepts of radiotherapy.
Staar et al. combined carboplatin with 5-FU and
hyperfractionated accelerated radiotherapy in a rando-
mized phase III trial [4] and presented comparable
results to studies based on cisplatin. The published
acute and late toxicity was moderate in this trial.
Another option of a treatment combination is the
addition of targeted therapy approaches e.g. antibodies
or small molecules. Squamous cell carcinomas of the
oro-, hypopharynx and larynx often show an overex-
pression of epidermal growth factor receptors (EGFR),
which is described to be associated with a poor prog-
nosis [5-7].
Cetuximab is a monoclonal antibody binding to the
extracellular EGFR domain. Intracellular phosphoryla-
tion of the EGFR is inhibited and consequently the
down stream signalling is deficient resulting in cell cycle
arrest and increased expression of pro-apoptotic
enzymes. Further effects of EGFR-inhibition that have
been already published are a reduction of cell prolifera-
tion and angiogenesis, as well as an increase of apoptosis
[8,9]. Cetuximab has been found to potentiate the
effects of chemotherapy and radiotherapy in experimen-
tal systems [8-10].
In a clinical setting, Bonner et al., in a pivotal phase
III trial, compared radiotherapy alone vs. radiotherapy
combined with cetuximab. In this trial, a statistically sig-
nificant increased overall survival and local control rate
could be found for the combined treatment regimen
[11,12]. Furthermore, beside skin reactions and a slight
increase of infusion reaction no further severe side
effects were reported. Apart from these medication spe-
cific side effects, no significantly increased toxicity
caused by the combination of radiotherapy and cetuxi-
mab could be found. This study was the first to demon-
strate in a clinical phase III setting that the combination
of radiotherapy and a monoclonal antibody against the
EGF-receptor resulted in a clear survival benefit. When
comparing the results of the Bonner study with chemor-
adiotherapy studies, it can be assumed that comparable
results could be achieved with this new combination. In
a retrospective literature review of chemoradiation data,
the Bonner regimen yielded comparable results, hence
this treatment is an alternative for patients who might
not complete standard therapy due to co-morbidities.
Unfortunately though, there is no phase III trial evaluat-
ing RCT vs. RT + cetuximab yet.
A further possibility to improve the therapeutic ratio
is the integration of modern techniques of radiotherapy
in current treatment schedules. Techniques like intensity
modulated radiotherapy (IMRT) can reduce the acute
and late toxicity and allow, through better protection of
the surrounding organs at risk, the application of higher
doses without increased toxicity and higher conformity.
The REACH trial is a phase II trial evaluating the
combination of modern radiotherapy techniques (IMRT)
and standard chemotherapy with the EGFR-inhibitor
cetuximab. The fractionation regimen applied for IMRT
corresponds to the established accelerated-hyperfractio-
nated regimen in conventional 3D-RT, hence the same
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fore, we would assume no increased risk concerning RT
with this modern technique. It seems that IMRT in this
specific set-up can even further reduce potential side
effects. Hence, better local control rates could be
achieved due to the advantages of IMRT in receiving a
better dose distribution in the target volume.
Methods/Design
Trial organization/coordination
REACH is a single-treatment group, bi-centric trial
designed by the study initiators of the Department of
Radiation Oncology of the University of Heidelberg. In
order to accelerate the data collection, the Helios Klini-
kum of Berlin Buch will also participate in this clinical
trial. The trial is carried out by the Department of
Radiation Oncology of the University of Heidelberg
which is therefore responsible for overall trial manage-
ment, trial registration (ClinicalTrials.gov Identifier:
ISRCTN87356938), database management, quality assur-
ance including monitoring and reporting. The trial is an
investigator initiated trial (IIT). Trial medication cetuxi-
mab (Erbitux®) is supplied by Merck KGaA, Darmstadt,
Germany.
Investigators
Patients will be recruited by the Departments of Radia-
tion Oncology at the University of Heidelberg and the
Helios Klinikum of Berlin-Buch. Due to the multi-modal
nature of the trial, all investigators are experienced
oncologists in the fields of radiation oncology and medi-
cal oncology.
Quality assurance
According to Good Clinical Practice (GCP) and other
applicable guidelines and regulations the side monitor-
ing will be carried out by an independent monitor con-
tracted by the sponsor.
Ethics, informed consent and safety
The final protocol was approved by the ethics commit-
tee of the Medical Faculty Heidelberg (AFmu-005/2009),
the local ethics committee Berlin and the Paul-Ehrlich-
Institute (PEI-registration number 789/01). This study
complies with the Declaration of Helsinki in its recent
German version, the Medical Association’sp r o f e s s i o n a l
code of conduct, principles of Good Clinical Practice
(GCP) guidelines and the Federal Data Protection Act.
The trial will also be carried out adhering to local legal
and regulatory requirements.
Written informed consent is obtained from each
patient in oral and written form before inclusion in
the trial. Nature, scope and possible consequences
of which will been explained by a physician. The
investigator will not undertake any measures specifi-
cally required for the clinical trial until valid consent
has been obtained.
Study design
T h eR E A C Hs t u d yi sap r o s p e c t i v ep h a s eI Is t u d y
combining the monoclonal EGF-receptor antibody
cetuximab (Erbitux®) with standard chemotherapy and
loco-regional irradiation therapy as intensity-modulated
radiation therapy (IMRT) in patients with locally
advanced squamous-cell carcinomas of oropharynx,
hypopharynx or larynx. Patients will be treated by the
Department of Radiation Oncology and Radiation Ther-
apy, University of Heidelberg, in co-operation with the
Helios Klinikum Berlin-Buch.
The primary endpoint of the study is the local-regio-
nal control (LRC).
The secondary endpoints are disease-free survival
(DFS), progression-free survival (PFS), overall survival
(OS), acute and late radiation effects, adverse events,
proteomics and genomics.
Patient selection
A total of 60 subjects with locally advanced, previously
untreated, primary non-metastatic, squamous cell carci-
noma located in the oro-, hypopharynx or larynx will be
included. Each subject will receive the trimodal treat-
ment as described above [radiation therapy (IMRT),
chemotherapy (carboplatin and 5-FU) and cetuximab].
Inclusion criteria:
￿ Signed written informed consent
￿ Age between 18 and 70 years
￿ Life expectancy > 6 months
￿ Histologically confirmed locally advanced (stage III
or IV), non-metastatic squamous cell carcinoma of
oro-, hypopharynx and larynx (T2-4,N x,M 0)
￿ Oral cavity or oro-, or hypopharynx or larynx as
the primary tumor site
￿ At least one uni-measurable lesion according to
RECIST criteria
￿ Karnofsky Performance Status > 70%
￿ Adequate bone marrow, liver and renal function:
wbc > 1.5 × 10
9/l, THC > 100 × 10
9/l, hb > 10.0 g/
d l ,B i l i<2 . 0g / d l ,S G O T ,S G P T ,A P ,G G T<3×
ULN, sCrea < 1.5 mg/dl
￿ Commitment to use of adequate contraception
Exclusion criteria:
￿ Previous chemotherapy, radiotherapy or surgery for
carcinoma of the head and neck
￿ Nasopharyngeal carcinoma
￿ Prior exposure to EGFR pathway targeting therapy
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ment, congestive heart failure NYHA III/IV, signifi-
cant neurological or psychiatric disorders including
dementia or seizures, active disseminated intravascu-
lar coagulation, symptomatic peripheral neuropathy
Common Toxicity Criteria (CTC) grade II or higher
as well as ototoxicity CTC II or higher except if due
to trauma or mechanical impairment due to tumor
mass.
￿ Pregnant or breast-feeding women
￿ Known allergic/hypersensitivity reaction to any
drugs scheduled for the study treatment
￿ Participation in other interventional trial within the
last 30 days
￿ Surgery within the last 30 days
￿ Known drug abuse
￿ Other previous malignancy within 5 years, with
exception of a history of a previous, adequately trea-
ted basal cell carcinoma of the skin or pre-invasive
carcinoma of the cervix
Work-up
Pathologically documented squamous cell oro-, hypo-
pharynx or larynx carcinomas will be sent for surgical
consultation. Patients receive a complete work-up
including examination under anaesthesia, head and neck
CT scans, chest x-ray, abdominal ultrasound and bone
scan. In case operation is either surgically or medically
impossible or the patient refuses to undergo the proce-
dure, in- and exclusion criteria will be examined and
eligibility will be analyzed. Should a patient meet the
trial conditions, information about participation in the
study including potential risks and benefits is given to
the patient. As soon as written consent is obtained,
patients can be included into the trial and the required
documentation will be provided by the study centre
(Studienzentrale Klinische Radiologie, Abt. Strahlenther-
apie und Radioonkologie, INF 400. 69120 Heidelberg).
After inclusion, each patient receives a RT-planning
CT-scan in an individually-adjusted precision immobili-
sation devices.
If a patient refuses treatment within the REACH trial,
standard combined chemoradiotherapy (Carboplatin/5-
FU, without cetuximab) will be offered.
Safety and discontinuation of treatment
Toxicities are classified byt y p ea n dg r a d ed u et oN C I
CTCAE v. 3.0, furthermore by duration, onset, and rela-
tionship to study treatment. Treatment of cetuximab-
induced adverse reactions is carried according to recom-
mendations by the manufacturer [13].
For grade 1 or grade 2 allergic reactions, a decrease of
infusion rate for current and subsequent infusions is
suggested. For ≥ grade 3, persistent grade 1 or grade 2
allergic reactions despite reduction of infusion rate, it is
recommended to discontinue treatment with cetuximab.
Skin reactions in terms of acne-like rash after cetuximab
are common. For patients facing a grade 3 acne-like
rash, cetuximab should be delayed for up to two subse-
quent infusions. Treatment also includes concomitant
topical and/or oral antibiotics where necessary. Therapy
can be resumed on resolution of the rash to < grade 2.
Cetuximab needs to be delayed on a second or third
occurrence of a grade 3 skin reaction for up to two con-
secutive cycles with dose reduction to 200 mg/m
2 or
150 mg/m
2 respectively. Any further occurrence of
grade 3 acne-like rash will lead to discontinuation of
cetuximab treatment according to the recommendations
of the summary of product characteristics.
Drug supply
Cetuximab (Erbitux®)
The monoclonal antibody cetuximab (Erbitux®) is pro-
vided by Merck KGaA, Darmstadt, Germany, and is
stored by the University Hospital Pharmacy,
Heidelberg.
The cetuximab dose applied in this setting corre-
sponds to the recommended and approved dosage
tested in combination with irinotecan in metastatic col-
orectal carcinoma [14]. Cetuximab is given with a load-
ing dose of 400 mg/m
2 of body surface as an
intravenous infusion on day 1. Subsequently, the regular
weekly dose during the radiotherapy is 250 mg/m
2 of
body surface on days 8, 15, 22, 29, 36, 43 (Figure 1). A
prophylactic premedication with corticosteroids and
antihistamines is required to reduce the incidence of
infusion-related reactions such as allergic/hypersensitiv-
ity reactions [13].
Figure 1 REACH treatment schedule: Cetuximab (Erbitux®) is
given at a loading dose of 400 mg/m
2 body surface on day 1,
the current dose during radiotherapy on days 8, 15, 22, 29, 36
and 43 is 250 mg/m
2 body surface. Chemotherapy (Carboplatin
70 mg/m
2 body surface/5-FU 600 mg/m
2 body surface) is given on
days 8-12 and 36-40. Radiotherapy (IMRT) starts one week after the
loading dose of cetuximab an day 8. From day 29 onwards, an
additional fraction of RT (concomitant boost) will be given to a total
dose of 69,9 Gy.
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Carboplatin will be applied at a dose of 70 mg/m
2 body
surface as a one-hour intravenous infusion on days 8-12
and 36-40 (corresponds to RT- week 1 and week 5 of
RT, Figure 1).
5-FU will be applied at a dose of 600 mg/m
2 of body
surface as an intravenous infusion over 24 hours on
days 8-12 and 36-40.
Radiation Therapy
Irradiation is applied as intensity-modulated radiation
therapy (IMRT) using either a 6 MV linear accelerator
(Siemens) with motoric multi-leaf collimator in a step
and shoot technique or a helical tomotherapy machine
(Tomotherapy, 6 MV). The primary tumor and cervical
lymph nodes receive a dose of 50,4 Gy in daily fractions
of 1.8 Gy (Monday to Friday). From study day 29
onwards, patients receive an additional fraction at 1.5
Gy per day (concomitant boost) to a total dose of 69.9
Gy (Figure 1). There is at least a 6-h interval between
the two daily fractions. Isocentre and patient positioning
are checked on the first fraction and then at least weekly
by CT. Radiation therapy can be carried out on an out-
patient basis apart from days 8-12 and 36-40 (che-
motherapy), unless the patient’s condition requires
hospital admission.
Target Volumes and dose prescription
The primary tumor and involved nodes - based on clini-
cal and endoscopic findings - constitute the gross tumor
volume (GTV). Nodes are considered positive if larger
than 1 cm in diameter or showing a necrotic centre.
The CTV contains the GTV and areas of potential
microscopic spread. CTV1 consists of the primary/posi-
tive lymph nodes (GTV) and a margin of approx. 1 cm,
CTV2 includes the GTV with a margin of about 2 cm
as well as the lymph node areas for elective nodal irra-
diation. The planning target volume (PTV) also
accounts for set-up variations and internal organ
motion, hence the CTV is usually expanded by a margin
of >0.5 cm. In cases where critical organs are directly
adjacent to either GTV or CTV, margins will, of course,
be adjusted. Doses are prescribed to the respective
PTVs: PTVHD (consisting of CTV1 plus margin) is pre-
s c r i b e dat o t a ld o s eo f6 9 , 9G yw h e r e a sP T V L D( C T V 2
plus margin) should receive a total dose of 50.4 Gy.
The PTVHD will at least be covered by the 95% pre-
scription isodose; in addition, no more than 20% of the
PTVHD should receive ≥ 110% and no more than 3% of
any part of the PTVHD or PTVLD should receive ≤
90% of the prescribed dose.
Doses of >110% of prescribed dose outside the target
volume should be limited to <1 cm
3.
For critical normal structures a margin of 0.5-1 cm
around the spinal cord may be added to create a
Planning Organ at Risk Volume (PRV). The dose to any
point within the spinal cord should not exceed 45 Gy to
any volume larger than 0.03 cm
3. The maximum doses
of 54 Gy to the brain stem are accepted. However, if
absolutely necessary, doses of max. 60 Gy can be toler-
ated to brain stem volumes < 60 Gy.
The mean dose to the parotid gland should be limited
to <26 Gy, alternatively at least 20 cc of the combined
volume of both parotid glands to < 20 Gy or at least
50% of one gland to <30 Gy. Whenever feasible, dose to
the larynx should be kept below 45 Gy.
T h ed o s et ot h eb r a c h i a lp l e x u sm u s tb el i m i t e dt o≤
60 Gy in patients with suspicious level IV node(s).
Mandible: 70 Gy should not be exceeded at any point.
Supportive Therapy
Antihistamines such as clemastine or dimentinden and
steroids are administered intravenously prior to cetuxi-
mab-application. Skin reactions, especially acne-like
rashes can be treated by topic or systemic antibiotics
(i.e. tetracyclines, metronidazole or nadifloxacine)
if necessary.
Whenever it is necessary, metoclopramide or 5-HT3-
antagonists are used for antiemesis.
Radiation induced skin reactions are treated according
to in-house protocols with mild moisturizing lotion or
local application of steroids.
Blood Samples
It is planned to collect approximately 300 ml of blood
from each study subject during his/her trial participa-
tion, i.e. within a period of maximum 60 consecutive
months. Potential risks of blood samplings are well pre-
dictable and include rare and mostly mild complications
such as vascular injury, reversible nerve irritation and/or
bleeding. Considering a potential gain of relevant infor-
mation on genomic/proteomic mechanisms and predic-
tive marker for clinical outcome in patients with
advanced cancer of the head and neck, blood sample
collection during the trial seems to be highly justifiable.
Adverse events
Radiotherapy-related toxicities will be assessed using the
NCI Common Toxicity Criteria (CTCAE v.3.0). Toxicity
will be evaluated at baseline, weekly during radiation
therapy (blood count, electrolytes, chemistry, clinical
examination, patient visits) and at follow-up visits.
Unacceptable toxicity is defined as unpredictable or irre-
versible grade 4 toxicity.
Expectable possible acute toxicities (up to 3 months
after irradiation) comprise skin toxicity (desquamation,
erythema, hyperpigmentation), nausea, vomiting, fatigue,
weight loss, loss of appetite, pneumonitis, haematologi-
cal toxicity with leucozytopenia, thrombozytopenia or
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and therefore usually resolve within 2-3 weeks. How-
ever, transient parenteral nutrition and hydration might
be necessary in some cases. All acute toxicities should
completely resolve within a few weeks post radiation
therapy.
Decisions regarding cetuximab as well as chemother-
a p yd o s ea d j u s t m e n tw i l lb em a d eb yu s i n gt h eg u i d e -
lines below and are based on haematological parameters
(ANC and platelets) monitored weekly during radiation
before each dose of cetuximab and chemotherapy.
Expedited reporting will be carried out according to
the local regulations.
Evaluation
Local response is evaluated in accordance with the
RECIST criteria (Response Evaluation Criteria in Solid
Tumours) [15].
￿ Complete remission (CR) is defined as complete
regression of the treated tumor mass (confirmation
after at least 4 weeks of treatment or later)
￿ Partial remission (PR) is defined as reduction of
sum of largest tumor diameters by at least 30%
￿ Stable disease (NC = no change) is defined as
neither PR nor PD
￿ Progressive disease (PD) is defined as increase of
sum of largest tumor diameters by 20%
Sample Size Calculation
The choice of number of patients is based on pragmatic
reasons. Therefore, the sample size analysis is replaced
by a power analysis giving the expected accuracy of the
results.
It is estimated that the two-year Local Regional Con-
trol rate will be 75 per cent. Given a constant hazard
rate over time (leading to an exponential distribution),
and assuming a two-year accrual time and a three-year
follow-up time (leading to a median observation time of
less than four years), with 60 patients treated the three-
year LRC rate can be estimated with a 95%-confidence
interval of approximate width of 18 per cent, i.e. if the
LRC estimate is 65 per cent, the limits can be expected
to be at 53 and 81 per cent.
Statistical Methods
The time to event for local regional control, disease-free
survival, progression-free survival, overall survival will
be calculated using a Kaplan-Meier estimate, along with
a 95 per cent confidence interval.
Acute and late radiation effects as well as adverse
events will be tabulated and listed by seriousness, sever-
ity, System Organ Class and relatedness.
Biometric analysis will be specified in more detail in
the statistical analysis plan which has to be authorized
before opening the database for analysis by the biome-
trician, the sponsor, and the LKP.
Discussion
Assuming that intensification of established chemora-
diotherapy by the addition of cetuximab can further
improve outcome, the primary end point of this study is
local regional control. Treatment-related side effects
should not be increased as compared to standard com-
bined chemoradiotherapy. As already discussed, the
combination of radiotherapy and cetuximab has shown
promising results with only marginally increased toxicity
or risks. In comparison with chemotherapeutic agents,
treatment with EGFR inhibitors is associated with lower
incidence of systemic side effects. Despite these benefits,
there are some commonly occurring side effects of
EGFR inhibitors (papulopustular rash, dry skin, itching,
hair and periungual alterations), which can result in
reduced quality of life as well as a reduction, interrup-
tion or discontinuation of cetuximab treatment. An eva-
luation of acute toxicity of skin and mucosa in patients
with head and neck cancer receiving radiotherapy (RT)
alone or in combination with radiotherapy plus che-
motherapy (RCT) or with cetuximab (RIT) showed a
grade 3 toxicity of the skin in 27,6% of the RIT patients
(vs. 0% of RT, 7% of CRT) [16]. Typical appearance of
grade 3 skin toxicity in RIT was a massive confluent
desquamation of the RT field. Acute grade 3 mucositis
was observed in 24,6% of RIT (vs. 12,5% of RT, 12,5% of
RCT). Cetuximab associated acneiform rash grade 3 was
observed in 7% of the RIT patients. Eight weeks after
RT, all patients had recovered from these side effects.
Cetuximab did not lead to a higher rate of RT interrup-
tions compared to RT or RCT. Budach et al. reported
on two patients with squamous-cell carcinoma of the
head and neck who had severe radiation dermatitis
while receiving a combination of radiotherapy and
cetuximab [17]. Severe radiation dermatitis may occur
after irradiation alone, but grade 4 lesions are rarely
observed. Coexisting conditions like previously received
chemotherapy or radiotherapy, liver or renal dysfunction
with possible alterations of pharmacodynamics of cetux-
imab, may predispose patients to the development of
more severe radiation dermatitis [17]. Another trial
reported that 49% of patients treated with cetuximab
and concurrent radiotherapy developed a grade III or IV
radiation dermatitis [18]. Hence, the incidence of these
severe skin reactions was twice as high compared to
that reported by Bonner et al. [11]. To evaluate the real
percentages of grade III and IV radiation dermatitis in
the treatment of cetuximab with concurrent radiother-
apy, a prospective, large-scaled study is needed.
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skin reactions remains to be clarified. With collecting
blood samples, we try to find strategies for the identifi-
cation of phenotypes and genotypes that are at risk of
skin toxicities.
Chemotherapies like cisplatin or 5-FU combined with
cetuximab have been used in the treatment of recurrent
and/or metastatic squamous cell carcinoma of the head
and neck. The results are promising and no increased or
overlapping toxicity was found. In the primary treatment
of locally advanced squamous cell carcinomas of head
and neck, combination of chemoradiotherapy and cetux-
imab resulted in increased acute side effects in a phase
II trial with 22 patients [6]. In the study, marked adverse
events occurred, including two deaths (one pneumonia
and one unknown cause), one myocardial infarction,
one bacteremia, and one atrial fibrillation. With a med-
ian follow-up of 52 months, the 3-year overall survival
rate was 76%, the 3-year progression-free survival rate
56%, and the 3-year locoregional control rate 71%.
Despite the positive clinical results, the trial was closed
prematurely. An investigation revealed no evidence that
the adverse events could be attributed to the addition of
cetuximab. Recently, the Radiation Therapy Oncology
Group (RTOG) initiated a phase II trial [19] based on
the protocol of Pfister et al. [20]. Concerning this pro-
posed trial, no increased risk or toxicity seemed evident
and therefore the benefit for the patients justifies con-
ducting the trial. Clear instructions are defined in the
protocol to ensure the safety of the patients.
Xerostomia is the most common late toxicity of radio-
therapy to the head and neck. IMRT can reduce the
dose delivered to the parotid glands. An analysis of
Nutting et al. showed reduction of xerostomia ≥G2
(LENT-SOMA scale) at 12 and 18 months post radia-
tion therapy from 74% (CRT) to 40% (IMRT) and 71%
(CRT) and 29% (IMRT) respectively [21]. A retrospec-
tive study of Clavel et al. compared toxicity and efficacy
of CRT and IMRT treated with concomitant chemother-
apy (carboplatin and 5-FU) for locally advanced oro-
pharyngeal cancer [22]. At a median follow-up of 33
months OS, DFS and LCR were significantly higher for
IMRT. Additionally, patients treated with IMRT had less
dermatitis and xerostomia at 24 and 36 months.
Author details
1Department of Radiation Oncology, University of Heidelberg, INF 400, 69120
Heidelberg, Germany.
2Department of Radiation Oncology, Helios Klinikum
Berlin Buch, Schwanenbecker Chaussee 50, 13125 Berlin, Germany.
3Department of Otorhinolaryngology, University of Heidelberg, INF 400,
69120 Heidelberg, Germany.
4Coordination Centre for Clinical Trials (KKS)
Heidelberg, University of Heidelberg, Vossstr. 2, 69120 Heidelberg, Germany.
Authors’ contributions
GH, ADJ, MWM, RK and JD planned and co-ordinate the study. GH, ADJ,
MWM, RK, KP, HH, MU, CS and JD are conducting the study. Medical care is
covered by GH, ADJ, KP, CS, MU, HH and MWM. MWM and RK are
responsible for the patient recruitment. GH, ADJ, RK, MU, HH and MWM
perform planning and radiation therapy. All authors read and approved the
final manuscript.
Competing interests
The authors declare that they have no financial or non-financial competing
interests. However, the trial medication (cetuximab, Erbitux®) and a financial
grant for study organisation are supplied by Merck KGaA, Frankfurter Str.
250, 64293 Darmstadt, Germany.
Received: 22 May 2010 Accepted: 26 November 2010
Published: 26 November 2010
References
1. Pignon JP, le Maitre A, Maillard E, Bourhis J, MACH-NC Collaborative Group:
Meta-Analysis of Chemotherapy in Head and Neck Cancer (MACH-NC):
An update on 93 randomised trials and 17,346 patients. Radiotherapy
and Oncology 2009, 92:4-14.
2. Budach W, Hehr T, Budach V, Belka C, Dietz K: A meta-analysis of
hyperfractionated and accelerated radiotherapy and combined
chemotherapy and radiotherapy regimens in unresected locally
advanced squamous cell carcinoma of the head and neck. BMC Cancer
2006, 6:28.
3. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J:
Hyperfractionated or accelerated radiotherapy in head and neck cancer:
a meta-analysis. Lancet 2006, 368(9538):843-854.
4. Staar S, Rudat V, Stuetzer H, Dietz A, Volling P, Schroeder M: Intensified
hyperfractionated accelerated radiotherapy limits the additional benefit
of simultaneous chemotherapy–results of a multicentric randomized
German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol
Phys 2001, 50(5):1161-1171.
5. Folprecht G, Lutz MP, Schoffski P, Seufferlein T, Nolting A, Pollert P:
Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe
combination for the first-line treatment of patients with epidermal
growth factor receptor expressing metastatic colorectal carcinoma. Ann
Oncol 2006, 17(3):450-456.
6. Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-
related peptides and their receptors in human malignancies. Crit Rev
Oncol Hematol 1995, 19(3):183-232.
7. Wilke H, Glynne-Jones R, Thaler J, : MABEL - A large multinational study of
cetuximab plus irinotecan in irinotecan resistant metastatic colorectal
cancer. J Clin Oncol 2006, 24(18S):Abstract 3549.
8. Baselga J: The EGFR as a target for anticancer therapy–focus on
cetuximab. Eur J Cancer 2001, 37(Suppl 4):S16-S22.
9. Fan Z, Baselga J, Masui H, Mendelsohn J: Antitumor effect of anti-
epidermal growth factor receptor monoclonal antibodies plus cis-
diamminedichloroplatinum on well established A431 cell xenografts.
Cancer Res 1993, 53(19):4637-4642.
10. Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K: In vivo
enhancement of tumor radioresponse by C225 antiepidermal growth
factor receptor antibody. Clin Cancer Res 2000, 6(2):701-708.
11. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB: Radiotherapy
plus cetuximab for squamous-cell carcinoma of the head and neck. N
Engl J Med 2006, 354(6):567-578.
12. Bonner JA, Ang K: More on severe cutaneous reaction with radiotherapy
and cetuximab. N Engl J Med 2007, 357:1872-3, author reply 1873.
13. Erbitux SmPC (Feb 2007). 2007, Ref Type: Report.
14. Siena S, Glynne-Jones R, Thaler J: MABEL - A large mulitnational study of
cetuximab plus irinotecan in irinotecan-resistant metastatic colorectal
cancer: Update on infusion related reactions (IRR). ASCO Gastrointestinal
Cancer Symposium 2007, Abstract 353.
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L,
Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther SG:
New guidelines to evaluate the response to treatment in solid tumors. J
Natl Cancer Inst 2000, 92:205-216.
16. Garcia-Huttenlocher HI, Timke C, Dinkel J, Huber PE, Debus J, Muenter MW:
Acute Toxicity of Skin and Mucosa in Patients with Head and Neck
Cancer Receiving Radiotherapy Alone or in Combination with
Chemotherapy or Cetuximab. Proceedings of the 5th Annual ASTRO
Meeting.
Habl et al. BMC Cancer 2010, 10:651
http://www.biomedcentral.com/1471-2407/10/651
Page 7 of 817. Budach W, Bölke E, Homey B: Severe cutaneous reaction during radiation
therapy with concurrent cetuximab. N Engl J Med 2007, 357:514-5.
18. Giro C, Berger B, Bölke E, Ciernuk IF, Duprez F, Locati L, Maillard S,
Ozsahin M, Pfeffer R, Robertson G, Langendijk JA, Budach W: High rate of
severe radiation dermatitis during radiation therapy with concurrent
cetuximab in head and neck cancer: Results of a survey in EORTC
institutes. Radiotherapy and Oncology 2009, 90:166-171.
19. RTOG 0522: a randomized phase III trial of concurrent accelerated
radiation and cisplatin versus concurrent accelerated radiation, cisplatin,
and cetuximab [followed by surgery for selected patients] for Stage III
and IV head and neck carcinomas. Clin Adv Hematol Oncol 2007,
5(2):79-81.
20. Pfister DG, Su YB, Kraus DH, Wolden SL, Lis E, Aliff TB: Concurrent
cetuximab, cisplatin, and concomitant boost radiotherapy for
locoregionally advanced, squamous cell head and neck cancer: a pilot
phase II study of a new combined-modality paradigm. J Clin Oncol 2006,
24(7):1072-1078.
21. Nutting C, A’Hern R, Rogers MS, Sydenham MA, Adab F, Harrington K,
Jefferies S, Scrase C, Yap BK, Hall E: First results of a phase III multicenter
randomized controlled trial of intensity modulated (IMRT) versus
conventional radiotherapy (RT) in head and neck cancer. 2009 ASCO
Annual Meeting, Abstract No: LBA6006, Citation: J Clin Oncol 2009, 27:18s,
(suppl; abstr LBA6006).
22. Clavel S, Nguyen D, Després P, Fortin B, Coulombe G, Donath D,
Soulières D, Charpentier D, Guertin L, F P: Nguyen-Tan: Higher dose per
fraction and shorter overall treatment time using intensity-modulated
radiation therapy versus conventional radiation therapy with concurrent
carboplatin and 5-fluorouracil for locally advanced oropharyngeal
carcinoma: A comparison of toxicity and efficacy. 2009 ASCO Annual
Meeting, Abstract No: 6038, Citation: J Clin Oncol 2009, 27:15s, (suppl; abstr
6038).
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/10/651/prepub
doi:10.1186/1471-2407-10-651
Cite this article as: Habl et al.: Treatment of locally advanced
carcinomas of head and neck with intensity-modulated radiation
therapy (IMRT) in combination with cetuximab and chemotherapy: the
REACH protocol. BMC Cancer 2010 10:651.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Habl et al. BMC Cancer 2010, 10:651
http://www.biomedcentral.com/1471-2407/10/651
Page 8 of 8